The total cost of cancer care in the US is about $146 billion, of which pancreatic cancer comprises $2.6 billion (1.8% of the total) and gastric cancer comprises $1.8 billion (1.3%). We have reviewed published studies presenting economic analysis of treatment or follow-up for patients with pancreatic or gastric cancer.
Relatively few studies report on economic evaluations of pancreatic cancer care.
There are also few economic studies for gastric cancer, although we identified three cost-effectiveness analyses.
In general, economic analyses in these areas are relatively unsophisticated, relying on charge data or simple multipliers (e.g., average cost per day in the hospital multiplied by days in the hospital), and are often limited to in-hospital costs (particularly studies for pancreatic cancer).
A wide range of costs is included in these studies and a variety of methodologies for assigning costs are used, making comparisons between studies difficult.
Future health economics research in this area should evaluate the costs and effectiveness of alternative practice patterns for gastric and pancreatic cancer ; conduct additional cost-effectiveness analyses of chemotherapeutic interventions ; consider quality of life, survival, stage at diagnosis, patient-borne costs, and complications of therapy ; and, take advantage of administrative data from large populations.
Mots-clés Pascal : Carcinome, Estomac, Adénocarcinome, Pancréas, Coût, Diagnostic, Traitement, Revue bibliographique, Homme, Tumeur maligne, Appareil digestif pathologie, Estomac pathologie, Pancréas pathologie, Economie santé
Mots-clés Pascal anglais : Carcinoma, Stomach, Adenocarcinoma, Pancreas, Costs, Diagnosis, Treatment, Bibliographic review, Human, Malignant tumor, Digestive diseases, Gastric disease, Pancreatic disease, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0289264
Code Inist : 002B13C01. Création : 16/11/1999.